Growth hormone (GH) response to GH-releasing hormone (GHRH) in asthmatic patients during long-term inhaled corticosteroids (ICS) treatment Source: Eur Respir J 2003; 22: Suppl. 45, 419s Year: 2003
Reduced bone density in inhaled corticosteroids-treated asthmatic patients showing decreased cortisol response to low-dose ACTH test Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008
Inhaled corticosteroids (ICS) and bone mineral density (BMD) - a follow-up study. The bronchial obstruction in Nord-Trøndelag study (BONT) Source: Eur Respir J 2004; 24: Suppl. 48, 601s Year: 2004
COPD: Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination and oxygen saturation (OS) in patients (pts) with different plasma surfactant protein D (SP-D) level Source: International Congress 2015 – COPD: notable points Year: 2015
Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β2 -agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 35s Year: 2003
Inhaled corticosteroid (ICS) induced metabolome changes in asthmatics. Source: Virtual Congress 2020 – Cutting edge science: novel molecules and mechanisms of airway diseases Year: 2020
Anti-inflammatory effect of montelukast (ML) and inhaled steroids (ICS) on clinical parameters and serum levels of NO in asthmatic children Source: Eur Respir J 2003; 22: Suppl. 45, 132s Year: 2003
E-cadherin (CDH-1 ) polymorphisms associate with airway remodeling, inflammation and FEV1 decline in asthma patients using inhaled corticosteroids (ICS) Source: Annual Congress 2010 - The impact of genes and environment on obstructive airway diseases Year: 2010
A low-dose (1.0 mcg) rapid ACTH test and adrenal function in adult patients with bronchial asthma treated with inhaled corticosteroids Source: Eur Respir J 2007; 30: Suppl. 51, 69s Year: 2007
The influence of inhalation thechnics at the long application of high dose inhaled corticosteroids on the mineral bone density (MBD) in children Source: Eur Respir J 2004; 24: Suppl. 48, 133s Year: 2004
Late Breaking Abstract - Blood eosinophil count (EOS) can accurately predict responsiveness to inhaled corticosteroids (ICS) in COPD, but only if measured while patients are not receiving steroids. Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018
Peak bone mineral density (BMD) in children with asthma treated for a mean of 14 years with inhaled budesonide Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler(R) Source: Eur Respir J 2002; 19: 1058-1063 Year: 2002
Effects of low dose inhaled theophylline (ADC4022) co-administered with budesonide on inflammatory markers, lung function, and quality of life in COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
The effect of inhaled and/or systemic corticosteroids on bone metabolism in asthmatic children Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma Year: 2007
The evaluation of bone density in the patients with bronchial asthma treated with glucocorticosteroids Source: Eur Respir J 2002; 20: Suppl. 38, 51s Year: 2002
Using hormone replacement therapy in perimenopausal women with bronchial asthma (BA) Source: Annual Congress 2007 - Novel issues in the treatment and control of asthma Year: 2007
Muscle regrowth in COPD patients induced by anabolic steroids is amplified by systemic glucocorticoids (GC): A potentiating interaction between GC and IGF-1? Source: Annual Congress 2011 - Challenges in chronic disease management: helping individuals with chronic lung disease remain stable Year: 2011
Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting2 -agonists (LABA) in moderately severe COPD Source: Annual Congress 2011 - Disease management in specific primary care populations Year: 2011